At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 147 enrolled
Drug / intervention
Centanafadine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets After Oral Administration in Adult Subjects With Binge Eating Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc.·interventional·Posted Nov 9, 2021·Updated Sep 9, 2025
In Brief
A Phase 2 clinical trial evaluating Centanafadine and Placebo for Binge-Eating Disorder. Completed, enrolled 147 participants across 25 sites.
Detailed Summary
The primary objective of this study is to assess the efficacy of 2 doses of centanafadine sustained-release (SR) (200 milligrams \[mg\] and 400 mg total daily dose \[TDD\]) compared with placebo in adults with moderate to severe binge eating disorder (BED).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBinge-Eating Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedNov 2021
Enrollment StartDec 2021
Primary CompletionAug 2022
TodayJul 2026
First PostedNov 9, 2021
Enrollment StartDec 22, 2021
Primary CompletionAug 19, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 4.6 years ago
Interventions
Centanafadinedrug
Sustained-release oral tablets
Placebodrug
Oral tablets